ITOS Company Profile and Key Details

iTeos Therapeutics, Inc. (NASDAQ:ITOS) closed at $10.15 USD, gaining $0.02 (0.20%) from the previous close of $10.13. The stock is currently mid-range between its 52-week high and low $4.80 and $17.63. With a market capitalization of about $448.68 million, iTeos Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.49). Key stats such as the average daily volume over the past year has been around 1.34 million shares, trading with heavier-than-usual volume. Headquartered in Watertown, MA, iTeos Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michel Detheux, the company employs approximately 173 people and listed since July 24, 2020. iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients.

ITOS has shown mixed momentum, losing -0.49% over the past week and 0.89% over the past quarter, though year-to-date performance is up 32.16%. Short-term trend indicators are mixed aligned (SMA20 0.21%, SMA50 0.17%, SMA200 22.49%). The stock’s 14-day RSI is 54.76 (neutral), while the ATR of 0.07 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -42.43% below its high and over 111.46% above its low.

iTeos Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.28. This means the shares are trading above this model’s fair value.

iTeos Therapeutics, Inc. has 44.21 million shares outstanding. The public float is 33.24 million shares, elevated short interest at 8.32% of float. This equals 2.97 million shares. The short ratio is 2.17 days. Institutional investors hold 90.6% of the float. Insiders own 0.35%. EcoR1 Capital, LLC holds 10.69 million shares, RA CAPITAL MANAGEMENT, L.P. has 5.71 million shares and GADICKE ANSBERT has 3.45 million shares.

iTeos Therapeutics, Inc. generated EPS of -$4.85 over the past year. Five-year average earnings growth is -34.39%. Wall Street analysts project EPS growth of -2.45% annually over the next five years. The latest quarter delivered EPS of -$1.51. The next quarter is forecast at -$1.35. Next year's EPS is expected at -$81.17. iTeos Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2025, missed forecasts by 34.82%. The prior quarter beat by -14.89%. Over the last six quarters, Apple has recorded several small beats. These include 4.9% in May 10, 2024.

iTeos Therapeutics, Inc. (NASDAQ:ITOS) shares are up 32.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows iTeos Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.89. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $31.83, suggesting 213.6% upside. Our AI forecast model points to short-term weakness (-0.3% over two weeks), a medium-term fall (-52.51% over three months), and a longer-term gain (135.07% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that iTeos Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.3%, with price expected at $10.12 by September 11, 2025, within a range of $9.93 to $10.29 3-Month Outlook: Projected fall of -52.51%, reaching $4.82 by November 26, 2025, with a range of $4.34 to $5.23. 1-Year Outlook: Projected gain of 135.07%, with price at $23.86 by August 28, 2026, within a range of $15.86 to $28.49.

iTeos Therapeutics, Inc. trades at a P/E ratio of -3.89, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.9 suggesting the stock is closer to book value. The P/FCF stands at -5.86, also below market averages.